Description
Glucolipid Metabolic Disease presents innovative peer-reviewed clinical and scientific research on the identification, prevention, control, and treatment of glucolipid metabolic diseases (GLMD). Due to lifestyle changes in recent years, this chronic disorder has resulted in an economic burden to healthcare systems around the world and poses a significant problem for public health. The ongoing prevalence of such metabolic diseases, with links to diabetes and obesity, indicates that current prevention and treatment methods are not working. Thus, it is imperative that finding new strategies to mitigate GLMD be undertaken by the world’s foremost experts.
Glucolipid Metabolic Disease publishes these efforts through leading research articles, commentaries, and reviews that discuss all aspects of GLMD. The journal places an emphasis on investigative reports that focus on areas such as the pathogenesis of lipemia, diabetes, steatohepatitis, arteriosclerotic cardio-cerebrovascular disease, and other factors which cause glucolipid metabolic disorder, including their complications, normal and pathologic organic function and intermediary metabolism, pharmacological mechanisms of drug and hormone action, and biochemical and molecular aspects of normal and abnormal biological processes. Pharmacologic and pharmacokinetics studies, meta-analyses, and molecular mechanism research are encouraged to be published as original articles.
Editorial Review Board
Editorial Board is currently being developed.